Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 6/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | UQCRB | P14927 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705348 | 0.89 | HSD17B2 (0.51) | HSD17B2HSD17B1UQCRBGAAMAPT | |
| SCHEMBL6705351 | 0.89 | HSD17B2 (0.51) | HSD17B2HSD17B1UQCRBGAAMAPT | |
| SCHEMBL6703763 | 0.86 | STAT3 (0.65) | HSD17B2HSD17B1STAT3UQCRBGAA | |
| SCHEMBL6705029 | 0.83 | STAT3 (0.69) | HSD17B2HSD17B1STAT3UQCRBGAA | |
| SCHEMBL6702498 | 0.83 | STAT3 (0.69) | HSD17B2HSD17B1STAT3UQCRBGAA | |
| SCHEMBL6705017 | 0.79 | HTR6 (0.59) | HSD17B2STAT3UQCRBGAAMAPT | |
| SCHEMBL6701386 | 0.78 | ALDH1A1 (0.57) | HSD17B2HSD17B1STAT3UQCRBGAA | |
| SCHEMBL6702482 | 0.76 | STAT3 (0.56) | HSD17B2STAT3UQCRBGAAMAPT | |
| SCHEMBL6703833 | 0.75 | STAT3 (0.61) | HSD17B2HSD17B1STAT3UQCRBGAA | |
| SCHEMBL6701392 | 0.74 | STAT3 (0.57) | HSD17B2STAT3UQCRBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693136-B1 | DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY | ABBOTT LABORATORIES | 2004-02-17 | — | — | US | claimed |
| US-20040019042-A1 | FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBVIE INC. | 2004-01-29 | — | — | US | claimed |
| US-6693136-B1 | DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY | ABBOTT LABORATORIES | 2004-02-17 | — | — | US | disclosed |
| US-20040019042-A1 | FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBVIE INC. | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019042-A1 | FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | P2RX3, P2RX1, P2RX2 | HSD17B2 2678/4885HSD17B1 2006/4885STAT3 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.